ArticleOncoTargets and therapy2019
Novel Tumor Suppressor lncRNA Growth Arrest-Specific 5 (GAS5) In Human Cancer.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 62 citations in OpenAlex.
- Review
- An Insight into the Emerging Role of Extracellular Vesicle-derived Noncoding RNAs in Colorectal Cancer.MicroRNA (Shariqah, United Arab Emirates) · 2026Review
- GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population.International journal of molecular sciences · 2025Article
- Epigenetic Regulation by lncRNA GAS5/miRNA/mRNA Network in Human Diseases.International journal of molecular sciences · 2025Review
- Long non-coding RNA involved in the carcinogenesis of human female cancer - a comprehensive review.Discover oncology · 2025Review
- The Multifaceted Role of lncRNA GAS5: A Pan-Cancer Analysis of Its Diagnostic, Prognostic, and Therapeutic Potential.Cureus · 2025Article
- Role of non-coding RNA through nanomedicine: the novel therapeutic and diagnostic approaches.BioImpacts : BI · 2025Review
- Exploring the role of noncoding RNAs in cancer diagnosis, prognosis, and precision medicine.Non-coding RNA research · 2024Review
- PGD: Shared gene linking polycystic ovary syndrome and endometrial cancer, influencing proliferation and migration through glycometabolism.Cancer science · 2024Article
- Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024Review
- lncRNA Biomarkers of Glioblastoma Multiforme.Biomedicines · 2024Review
- lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways.Medical oncology (Northwood, London, England) · 2024Review
- The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers.Frontiers in oncology · 2024Review
- Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA.International journal of molecular sciences · 2023Review
- Prenatal alcohol exposure alters mRNA expression for stress peptides, glucocorticoid receptor function and immune factors in acutely stressed neonatal brain.Frontiers in neuroscience · 2023Article
- Long non-coding RNAs and JAK/STAT signaling pathway regulation in colorectal cancer development.Frontiers in genetics · 2023Review
- Review
- The maternal-placental-fetal interface: Adaptations of the HPA axis and immune mediators following maternal stress and prenatal alcohol exposure.Experimental neurology · 2022Review
- Research Progress of Long Non-Coding RNA GAS5 in Malignant Tumors.Frontiers in oncology · 2022Review
- The roles of long non-coding RNAs in lung cancer.Journal of Cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long noncoding RNAs (lncRNAs) play crucial regulatory roles in fundamental biological processes, and deregulations of lncRNAs have been linked to numerous human diseases, especially cancers. Of particular interest in this regard is lncRNA GAS5, which is mainly identified as a tumor suppressor in several cancers. GAS5 was significantly low expressed in multiple cancers and was associated with clinic-pathological characteristics and patient survival, indicating a novel potential diagnostic and prognostic biomarker, and a therapeutic target for cancer. Functionally, GAS5 is involved in cell proliferation, metastasis, invasion, apoptosis, epithelial-mesenchymal transition (EMT), and drug resistance, among others, via multiple molecular mechanisms, such as binding to DNA sequences, forming RNA-DNA triplex complex, triggering or suppressing the expression of genes, binding proteins to form chromatin-modifying complex, which activates or represses gene expression, and acting as miRNA sponge to suppress miRNA expression, leading to regulation of miRNA target genes. This review provides an overview of the current state of knowledge and role of GAS5 in clinical relevance, biological functions and molecular mechanisms underlying the dysregulation of expression and function of GAS5 in cancer. Finally, the potential prospective role as diagnostic and prognostic biomarker and therapeutic target in cancer is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.